Shopping Cart
Remove All
Your shopping cart is currently empty
Ziresovir
😃Good
Catalog No. T13401Cas No. 1422500-60-4
Alias RO-0529, AK0529
Ziresovir (RO-0529) is a respiratory syncytial virus fusion protein (RSV F) inhibitor that inhibits RSV activity and can be used in the study of syncytial virus sensing.
Ziresovir
😃Good
Purity: 99.92%
Catalog No. T13401Alias RO-0529, AK0529Cas No. 1422500-60-4
Ziresovir (RO-0529) is a respiratory syncytial virus fusion protein (RSV F) inhibitor that inhibits RSV activity and can be used in the study of syncytial virus sensing.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $173 | In Stock | In Stock | |
| 5 mg | $289 | In Stock | In Stock | |
| 10 mg | $455 | In Stock | In Stock | |
| 25 mg | $818 | In Stock | In Stock | |
| 50 mg | $1,190 | In Stock | In Stock | |
| 100 mg | $1,630 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $279 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products. If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
Batch Information
Select Batch
Purity:99.92%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Ziresovir (RO-0529) is a respiratory syncytial virus fusion protein (RSV F) inhibitor that inhibits RSV activity and can be used in the study of syncytial virus sensing. |
| Targets&IC50 | RSV (WT):0.003 μM (EC50), D489A (RSV,Mutant strain):> 10μM (EC50), D486N (RSV,Mutant strain):2.1 μM (EC50), RSV F:3 nM (EC50) |
| In vitro | With EC50/EC90 values (μM) of 0.003/0.005 (WT), 2.1/10.0 (D486N), and >10/>10 (D489A), Ziresovir exhibits different efficacy in Wild Type (WT) and Mutant Strains RSV, respectively[1].Inhibiting the RSV F protein-induced cell–cell fusion process, RO-0529 (100 nM; 4 d) suppresses the syncytia formation induced by the RSV F protein[1]. |
| In vivo | Ziresovir (12.5 mg/kg, 50 mg/kg; p.o.; twice daily; 4 d) reduces RSV titer in the mouse lung[1]. With a single oral dose of 10 mg/kg, Ziresovir exhibits good exposure and 32% bioavailability in male Wistar-Han rats[1]. A single oral dose of 150 mg/kg results in higher lung distribution than plasma in CD-1 mice[1]. |
| Synonyms | RO-0529, AK0529 |
| Molecular Weight | 439.53 |
| Formula | C22H25N5O3S |
| Cas No. | 1422500-60-4 |
| Smiles | Cc1ccc2nc(nc(NCC3(N)COC3)c2c1)N1CCS(=O)(=O)c2ccccc2C1 |
| Relative Density. | 1.390 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 38 mg/mL (86.46 mM), Sonication and heating are recommended.  | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.55 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Ziresovir | purchase Ziresovir | Ziresovir cost | order Ziresovir | Ziresovir chemical structure | Ziresovir in vivo | Ziresovir in vitro | Ziresovir formula | Ziresovir molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.